Hyperbaric oxygen therapy reduces neuroinflammation and supports brain health in Parkinson's disease
Hyperbaric oxygen therapy reduces neuroinflammation and supports brain health in Parkinson's disease
Understanding Parkinson's disease and how HBOT supports neurological health
Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra, a region of the basal ganglia critical for movement control. The resulting dopamine deficiency causes the hallmark motor symptoms of Parkinson's: tremor, rigidity, slowness of movement (bradykinesia) and postural instability. Non-motor symptoms — including cognitive decline, fatigue, depression and autonomic dysfunction — often become equally burdensome as the disease advances.
Current standard treatments, including levodopa and other dopaminergic medications, address symptoms but do not slow the underlying neurodegeneration. Research increasingly points to neuroinflammation, mitochondrial dysfunction and oxidative stress as core mechanisms of dopaminergic neuron loss — all of which are directly addressed by HBOT.
HBOT increases cerebral oxygen delivery, suppresses neuroinflammation through downregulation of pro-inflammatory cytokines, upregulates endogenous antioxidant defenses and activates neurotrophic gene expression. While HBOT is not a cure for Parkinson's, growing clinical evidence supports it as a meaningful adjunctive therapy that can improve motor and cognitive function, reduce fatigue and improve quality of life.
Tremor at rest, rigidity and slowed movement (bradykinesia)
Balance and gait disturbances increasing fall risk
Cognitive impairment and increased dementia risk
Fatigue, depression and anxiety
Speech and swallowing difficulties
Autonomic dysfunction including blood pressure dysregulation and bladder symptoms
How HBOT supports brain health in Parkinson's disease
HBOT addresses three of the core mechanisms driving Parkinson's progression: neuroinflammation, oxidative stress and cerebral hypoperfusion — while activating neuroprotective responses that support remaining dopaminergic neurons.
Reduces neuroinflammation driving disease progression
Improves cerebral blood flow and oxygenation
Activates neuroprotective gene expression
Improves motor function and reduces tremor
Enhances cognitive function and reduces fatigue
Reduces oxidative stress
For Providers
Research on HBOT in Parkinson's disease
Research into HBOT for Parkinson's disease is ongoing and growing. While Parkinson's is not currently a Medicare-approved indication for HBOT, the mechanistic rationale is compelling and early clinical evidence is encouraging.
Neuroinflammation and HBOT: Liu et al. published a study in Neurological Research (2015) demonstrating that HBOT significantly reduced neuroinflammatory markers and slowed dopaminergic neuron loss in a rodent model of Parkinson's disease, with treated animals showing improved motor performance on behavioral testing. The authors proposed that HBOT's anti-inflammatory effects on microglia may be neuroprotective in Parkinson's. [Liu W et al. Neurol Res. 2015;37(5):469–477. PMID: 25803882]
Oxidative stress reduction: HBOT at therapeutic pressures has been shown to upregulate superoxide dismutase and catalase — the primary endogenous antioxidant enzymes — in multiple published studies. Since oxidative stress is a central mechanism of dopaminergic neuron death in Parkinson's, this antioxidant response is mechanistically relevant. [Rothfuss A et al. Carcinogenesis. 2001;22(12):1979–1986. PMID: 11751428]
Cerebral hypoperfusion in Parkinson's: PET and SPECT imaging studies have consistently demonstrated regional cerebral hypoperfusion in Parkinson's disease patients, particularly in the basal ganglia and frontal cortex. HBOT significantly increases cerebral oxygen delivery, and studies in related conditions suggest improved perfusion and metabolic activity following treatment courses. [Nagata K et al. Eur J Nucl Med. 1996;23(11):1421–1429. PMID: 8929298]
Clinical pilot evidence: Poff et al. and other researchers have reviewed the theoretical and clinical basis for HBOT in neurodegenerative diseases, noting that the combination of improved oxygenation, reduced neuroinflammation and neurotrophic factor activation provides a compelling rationale for continued investigation. Multiple clinical case reports and small series have reported meaningful motor and cognitive improvements following HBOT in Parkinson's patients. [Poff AM et al. Med Gas Res. 2019;9(4):221–226. PMID: 31898608]
Important note: Parkinson's disease is not a Medicare-approved indication for HBOT, and randomized controlled trials in humans are limited. The evidence base is mechanistic and early-clinical at this stage. We present the existing evidence honestly and encourage patients to discuss HBOT with their neurologist.
Our Parkinson's HBOT protocol at Bay Area Hyperbarics
HBOT for Parkinson's is an adjunctive therapy. We work alongside your neurologist to support improved quality of life and function — not to replace your standard Parkinson's medications or care.
Neurological assessment and care team coordination
Our medical team reviews your current Parkinson's status, medications and treatment goals. We coordinate with your neurologist to ensure HBOT is integrated as an adjunct to your existing medical care, not a replacement for it.
Daily HBOT sessions to improve brain oxygenation and reduce inflammation
You breathe 100% oxygen at 1.5 to 2.0 atmospheres absolute for approximately 60 to 90 minutes per session. Neurological conditions typically begin with a course of 40 sessions over 8 to 10 weeks, with periodic maintenance courses thereafter based on response.
Outcome tracking and maintenance planning
We track motor function, cognition, fatigue and quality of life measures throughout your course of treatment. Based on your response, we work with you and your neurologist to plan appropriate maintenance sessions to sustain the benefits achieved.
Frequently Asked Questions
Answers to the questions Parkinson's patients and families most often ask about hyperbaric oxygen therapy.
No. HBOT is not a cure for Parkinson's disease, and no current treatment reverses the underlying neurodegeneration. HBOT works as an adjunctive therapy — alongside your standard neurological care and medications — to improve cerebral oxygenation, reduce neuroinflammation and support the health of remaining neurons. Many patients report improvements in motor function, cognition, fatigue and quality of life following HBOT.
Living with Parkinson's? Ask us about HBOT
Bay Area Hyperbarics offers HBOT as a supportive adjunctive therapy for Parkinson's disease patients seeking to improve function and quality of life alongside their standard neurological care. Call us to learn more.
